Abstract
Objective: When one TNFα blocker (etanercept or infliximab) has failed, to determine whether it makes sense to treat patients with the other.
Patients and methods: Since 1999 patients treated with etanercept or infliximab have been systematically followed up at our institution in the STURE database. We identified 31 patients who had received both agents.
Results: Eighteen patients received etanercept first; discontinuation was mostly due to lack of efficacy. DAS28 values had improved only slightly with etanercept, with a mean (SEM) best DAS28 value of 4.8 (0.6). After switching to infliximab, the mean best DAS28 was 3.6 (0.6)—significantly better than the previous result (p<0.05). Similarly, the mean best ACR-N during etanercept treatment was 17.2 (6.65) and during subsequent infliximab treatment 40.4 (10.6) (p = 0.08). Thirteen patients received infliximab first; discontinuation was mainly due to adverse events. The best DAS28 value achieved during etanercept was 3.6 (0.4) compared with 4.1 (0.4) for infliximab (p<0.05), but the change in DAS28 was not different and ACR-N were similar for infliximab and etanercept in this group.
Conclusion: For patients with insufficient efficacy from etanercept, treatment with infliximab provided better results, suggesting that a trial of infliximab is reasonable for such patients. For patients who discontinued infliximab owing to adverse events, treatment with etanercept gave at least similar clinical efficacy. Taken together, these data provide support for a trial of the reciprocal TNFα blocker in patients when one such agent has failed.
Full Text
The Full Text of this article is available as a PDF (274.7 KB).
Figure 1 .
(A) Disease activity by DAS28 in patients treated first with etanercept, then with infliximab. Values shown are the mean value at baseline (before etanercept treatment), mean best value during etanercept treatment, mean value at last visit while on etanercept (when the decision to switch was made), mean best value with infliximab. Comparisons are by paired two tailed Student's t test. (B) Swollen joint count in patients treated first with etanercept, then with infliximab. Values shown are the means at baseline and after three months for each treatment. Comparisons are by paired two tailed Student's t test.
Figure 2 .
(A) Disease activity by DAS28 in patients treated first with infliximab, then with etanercept. Values shown are the mean value at baseline (before infliximab treatment), mean best value during infliximab treatment, mean value at last visit while on infliximab (when decision to switch was made), mean value just before starting etanercept treatment, and mean best value on etanercept. Comparisons are by paired two tailed Student's t test. (B) Swollen joint count in patients treated first with infliximab, then with etanercept. Values shown are the means at baseline and after three months for each treatment. Comparisons are by paired two tailed Student's t test.
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Bathon J. M., Martin R. W., Fleischmann R. M., Tesser J. R., Schiff M. H., Keystone E. C., Genovese M. C., Wasko M. C., Moreland L. W., Weaver A. L. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med. 2000 Nov 30;343(22):1586–1593. doi: 10.1056/NEJM200011303432201. [DOI] [PubMed] [Google Scholar]
- Felson D. T., Anderson J. J., Boers M., Bombardier C., Furst D., Goldsmith C., Katz L. M., Lightfoot R., Jr, Paulus H., Strand V. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. 1995 Jun;38(6):727–735. doi: 10.1002/art.1780380602. [DOI] [PubMed] [Google Scholar]
- Geborek P., Crnkic M., Petersson I. F., Saxne T., South Swedish Arthritis Treatment Group Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: clinical experience using a structured follow up programme in southern Sweden. Ann Rheum Dis. 2002 Sep;61(9):793–798. doi: 10.1136/ard.61.9.793. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Husni M. Elaine, Maier Agnes L., Mease Philip J., Overman Steven S., Fraser Patricia, Gravallese Ellen M., Weinblatt Michael E. Etanercept in the treatment of adult patients with Still's disease. Arthritis Rheum. 2002 May;46(5):1171–1176. doi: 10.1002/art.10231. [DOI] [PubMed] [Google Scholar]
- Kruithof E., Van den Bosch F., Baeten D., Herssens A., De Keyser F., Mielants H., Veys E. M. Repeated infusions of infliximab, a chimeric anti-TNFalpha monoclonal antibody, in patients with active spondyloarthropathy: one year follow up. Ann Rheum Dis. 2002 Mar;61(3):207–212. doi: 10.1136/ard.61.3.207. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Lipsky P. E., van der Heijde D. M., St Clair E. W., Furst D. E., Breedveld F. C., Kalden J. R., Smolen J. S., Weisman M., Emery P., Feldmann M. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med. 2000 Nov 30;343(22):1594–1602. doi: 10.1056/NEJM200011303432202. [DOI] [PubMed] [Google Scholar]
- Moreland L. W., Baumgartner S. W., Schiff M. H., Tindall E. A., Fleischmann R. M., Weaver A. L., Ettlinger R. E., Cohen S., Koopman W. J., Mohler K. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med. 1997 Jul 17;337(3):141–147. doi: 10.1056/NEJM199707173370301. [DOI] [PubMed] [Google Scholar]